Memantine for treatment of moderate or severe Alzheimer's disease patients in urban China: clinical and economic outcomes from a health economic model

作者：Hu, Shanlian^*; Yu, Xin; Chen, Shengdi; Clay, Emilie; Toumi, Mondher; Milea, Dominique

来源：Expert Review of Pharmacoeconomics and Outcomes Research: Informing Decision-Making in the Delivery of Cost-Effective Healthcare , 2015, 15(4): 565-578.

DOI：10.1586/14737167.2015.1065734

• aggression
• Alzheimer's disease
• cost-saving
• disease burden
• memantine
• pharmacoeconomic

Objective: To estimate the clinical and economic benefits of memantine treatment initiated in moderate Alzheimer's disease (AD) in China, compared with initiation in severe AD only. Methods: A Markov model with a 5-year time horizon simulated moderate patients' progression through health states. Two groups were compared: patients receiving memantine from the moderate stage (i.e., at model entry), continuing treatment when reaching the severe stage; patients initiating memantine only when they developed severe disease. Results: After 5 years, fewer patients receiving memantine from the moderate stage were severe (49%), dependent (59%) or aggressive (47%) compared with moderate patients who initiated treatment from severe stage only (58, 67 and 55%, respectively). Total cost of care was lower for treatment from moderate stage (67 billion RMB) when compared with treatment from severe stage (73 billion RMB). Conclusions: In China, AD treatment with memantine from the moderate stage could result in substantial cost savings.

• 出版日期2015-8
• 单位上海市闵行区中心医院; 复旦大学; 上海交通大学